“Antibody-drug conjugates stand as a cornerstone in modern oncology, combining the highly specific targeting capability of antibodies with the potent cytotoxic effect of small-molecule drugs. Their promise lies in delivering effective and focused tumor treatment while mitigating the systemic toxicities often associated with traditional chemotherapy. However, this promise comes hand in hand with the added complexity posed by the conjugation chemistry, linker design, payload stability, and biologic interplay with the patient’s immune system.”
This review highlights critical analytical techniques necessary for the characterization of ADCs, emphasizing their physicochemical properties, biological activity, stability assessments, and regulatory implications. Employing robust analytical methods is essential throughout the ADC development process to guarantee both therapeutic effectiveness and safety, ultimately positioning ADCs as a vital element in contemporary cancer treatment strategies.
Read our white paper ‘Analytical Techniques for Antibody-Drug Conjugates (ADCs): Comprehensive Insights’ by Vara Prasad Chandrabatla, Associate Director of Analytical R&D at Veranova, to learn more.
